• Better therapies being developed to target patient concerns.
• Improved trial designs focused on patient needs.
• Better communication from the research community
• And more informed/engaged patients and families.
The patient community brings a combination of the lived experience of the disease, a sense of urgency, and an array of career backgrounds and skill sets that can all contribute immensely to the research process. Hopefully, having a clearer view of the trial pipeline will enable greater awareness around opportunities for researcher/patient collaboration.Sue Buff, Parkinson’s care partner and research advocate.
It is currently very difficult for members of the Parkinson’s community to attain a clear understanding of what is happening within the field of clinical trials for the condition. Large databases, like the US National Institutes of Health’s ClinicalTrials.gov website, provide a search engine to a bewildering array of trials. Websites like the Michael J Fox Foundation’s ‘Fox Trial Finder’ and Parkinson’s UK ‘Take Part Hub’ allow individuals to find research studies being conducted within their local area.
However, none provide a concise overview of the broader domain of Parkinson’s research focused on new therapies to treat the condition. It is envisaged that this broad identification of research trends and emerging treatments will facilitate research progression and ultimately it is hoped, a cure for Parkinson’s.
Inspired projects by Parkinson’s research advocates like Kevin McFarthing’s ‘Parkinson’s Hope List’ and Sue Buff’s ‘PDTrialTracker’ have provided the Parkinson’s community with useful resources that represent excellent sources of information and show examples of proactive advocacy and engagement.
Recently, Kevin and Sue along with another research advocate Gary Rafaloff, have pooled their skills and collaborated with the CPT research team to compile a wide-ranging analysis of the current pipeline of clinical trials evaluating new and emerging therapies for Parkinson’s. Their report has now been published in the Journal of Parkinson’s Disease.
The real joy of being part of this study was that it was driven by committed and fully engaged research advocates who gave up their free time to provide everyone with an extremely useful resource. It has been inspiring to be part of the project, but full credit belongs to Sue, Kevin and Gary.Dr. Simon Stott, Deputy Director of Research, Cure Parkinson’s
Their study involved collecting all of the available information from the ClinicalTrials.gov website regarding ongoing clinical trials for Parkinson’s. After excluding observational and non-drug related studies, they found that there were 145 active registered trials being conducted between January 2019 and January 2020. Of these, 88 trials were focused on symptomatic relief while the remaining 57 trials aimed to slow, stop or reverse the long-term progression of Parkinson’s.
There are 3 phases to the clinical development of drugs: Phase 1 determines the safety of the drug, Phase 2 investigates safety again and looks for signs of efficacy, and Phase 3 seeks to determine the long-term safety and efficacy of the drug being tested. Encouragingly, the team found a wide distribution of studies across these 3 phases, showing a rich and broad range of therapies targeting different approaches to tackling Parkinson’s. From stem cell-based transplantation and boosting the body’s immune system (immunotherapy), to manipulation of the bacteria in the gut and medication which removes excess iron from the brain; many facets of the condition are being tackled.
The researchers noted that 50 of the 145 trials involved the repurposing of drugs that are already being clinically used for other conditions. Repurposing of drugs represents a faster means of getting new treatments through the clinical trial process and into the Parkinson’s clinic. Many of the repurposed trials for Parkinson’s are supported by Cure Parkinson’s, such as the exenatide Phase 3 study, the ambroxol Phase 2 study, the UDCA Phase 2 study, and the simvastatin Phase 2 study (the results of which will be announcing later this year).
The results presented in this study highlight the tremendous impact that a modest charity like Cure Parkinson’s can have on an important global research effort to slow, stop or reverse Parkinson’s. Through programmes like the International Linked Clinical Trials initiative, Cure Parkinson’s is a driving force in the current drug pipeline for Parkinson’s. As this table demonstrates, fully one third (35%) of disease modifying trials featured in the report involve agents that have been evaluated by the international Linked Clinical Trials Committee, and more than 10% of all the disease modifying trials conducted worldwide are being funded by Cure Parkinson’s. As the international Linked Clinical Trials programme enters its 10th year, Cure Parkinson’s is committed to increasing that impact by supporting more trials as we seek to cure this condition once and for all.